Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Thursday at a closing price of $0.33, with 3.61 million shares of worth about $1.19 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -42.18% during that period and on July 24, 2025 the price saw a gain of about 14.59%. Currently the company’s common shares owned by public are about 257.85M shares, out of which, 229.65M shares are available for trading.
Stock saw a price change of 20.18% in past 5 days and over the past one month there was a price change of 30.93%. Year-to-date (YTD), ADAP shares are showing a performance of -72.54% which decreased to -38.31% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.20 but also hit the highest price of $1.48 during that period. The average intraday trading volume for Adaptimmune Therapeutics Plc ADR shares is 934.43K. The stock is currently trading 25.02% above its 20-day simple moving average (SMA20), while that difference is up 23.79% for SMA50 and it goes to -30.88% lower than SMA200.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) currently have 257.85M outstanding shares and institutions hold larger chunk of about 34.04% of that.
The stock has a current market capitalization of $85.68M and its 3Y-monthly beta is at 2.25. It has posted earnings per share of -$0.27 in the same period. It has Quick Ratio of 1.79. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADAP, volatility over the week remained 9.17% while standing at 7.32% over the month.
Analysts are in expectations that Adaptimmune Therapeutics Plc ADR (ADAP) stock would likely to be making an EPS of -0.13 in the current quarter, while forecast for next quarter EPS is -0.1 and it is -0.49 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.14 which is -0.12 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.24 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -75.44% while it is estimated to decrease by -50.43% in next year. EPS is likely to shrink at an annualized rate of -24.90% for next 5-years, compared to annual growth of 26.53% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on June 26, 2025 offering a Neutral rating for the stock and assigned a target price of $0.50 to it. Coverage by H.C. Wainwright stated Adaptimmune Therapeutics Plc ADR (ADAP) stock as a Buy in their note to investors on July 30, 2024, suggesting a price target of $4 for the stock. On May 30, 2024, Scotiabank Initiated their recommendations, while on March 24, 2023, Bryan Garnier Initiated their ratings for the stock with a price target of $3.60. Stock get a Buy rating from Guggenheim on January 03, 2023.
